Martindale Pharma Announces Line Extensions And Patient-Focused Improvements To Packs Of Tapclob

Wooburn Green, Buckinghamshire, December 7 2015: Martindale Pharma, a leading UK-based international specialty pharmaceutical company, is pleased to announce an additional presentation to the Tapclob range, the UKs first licensed oral liquid suspension of clobazam. From 7th December 2015, Tapclob will be available in a 250ml bottle for both strengths (5mg/5ml and 10mg/5ml) as well as the 150ml bottle. This larger size will reduce the number of bottles needed to be used for a significant number of patients receiving Tapclob.

In addition, from 7th December 2015, all packs of Tapclob will include a 5ml oral syringe and a 30ml dosing cup. These items will make it even easier for patients and their carers to accurately measure the required dose of Tapclob. Michael Clark, Chief Marketing Officer of Martindale Pharma, commented:

“We are pleased with these two positive additions to the Tapclob range. This shows that Tapclob is continuing to adapt to the needs of both prescribers and patients alike in a therapeutic area where ease of use is really important.”

For further information on these products please contact customer services on 0800 0287933 or at connect@martindalepharma.co.uk, or for medical enquiries please contact medical information at medinfo@martindalepharma.co.uk.

For further information on Tapclob 5mg/5ml and 10mg/5ml Oral Suspension please contact Martindale Pharma on 0800 0287933 or our Medical Information Team on 01708 382145 or via medinfo@martindalepharma.co.uk.
MORE ON THIS TOPIC